SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K Current Report, dated May 23, 2024, details the results of the 2024 Annual Meeting of Stockholders for Athira Pharma, Inc. The report covers corporate governance actions taken on May 23, 2024, including the election of directors, ratification of auditors, and approval of a charter amendment. The filing does not contain financial performance data for a specific reporting period.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report rather than a financial statement.
Material Changes and Voting Results
On the record date of March 26, 2024, the Company had 38,326,652 shares of common stock outstanding. At the Annual Meeting, 27,358,709 shares (approximately 71.38%) were present or represented by proxy. The following proposals were voted upon:
- Proposal 1: Election of Class I Directors
- Barbara Kosacz: Elected (16,194,646 For; 4,121,308 Withhold)
- Mark Litton: Elected (18,117,972 For; 2,197,982 Withhold)
- Michael Panzara: Elected (17,787,498 For; 2,528,456 Withhold)
- Proposal 2: Ratification of Independent Auditor
- Ernst & Young LLP was ratified for the fiscal year ending December 31, 2024 (27,199,785 For; 59,069 Against).
- Proposal 3: Amendment to Certificate of Incorporation
- Stockholders approved an amendment to limit the liability of officers as permitted by Delaware law (19,365,835 For; 602,307 Against).
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. The primary focus is the certification of voting results and the filing of the conformed amendment to the Certificate of Incorporation (Exhibit 3.1).
Key Facts for Investor Verification
- Verify the effective date and specific language of the officer liability limitation amendment filed with the Delaware Secretary of State.
- Confirm the tenure of the newly elected Class I Directors (Barbara Kosacz, Mark Litton, and Michael Panzara) through the 2027 annual meeting.
- Review the definitive proxy statement filed on April 9, 2024, for detailed background on the proposals and director biographies.
- Note that the filing contains no financial performance updates; refer to the most recent 10-Q or 10-K for financial metrics.